<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134364</url>
  </required_header>
  <id_info>
    <org_study_id>KNUMC 2016-02-002</org_study_id>
    <nct_id>NCT04134364</nct_id>
  </id_info>
  <brief_title>The Effect of Lamina-G on Gastrointestinal Symptom After Gastric Biopsy</brief_title>
  <official_title>The Effect of 3-day Oral Administration of Lamina-G on Epigastric Pain or Soreness After Gastric Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyungpook National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sometimes, subjects complain about gastrointestinal symptoms after esophagogastroduodenoscopy
      and biopsy. The aim of this study is to investigate the effect of sodium alginate (Lamina-GÂ®)
      on biopsy-related gastrointestinal symptom.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open labeled, single-center randomized controlled trials. Patients who
      underwent upper enoscopy with biopsy were randomly assigned to medication and control group.
      In the medication group, sodium alginate was administered after EGD during 3 days. All
      patients underwent a questionnaire to check the presence of gastrointestinal symptoms at
      baseline and on the day after return home. After 3 days, gastrointestinal symptoms were
      investigated by telephone survey. Gastrointestinal symptom was scaled by upper
      gastrointestinal symptom rate score (GSRS). Upper GSRS contains 8 items and 3 scales;
      abdominal pain (abdominal pain, epigastric pain/hunger soreness, nausea), reflux symptom
      (Heartburn/reflux/belching gas), indigestion symptom (abdominal distension, borborygmus).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2017</start_date>
  <completion_date type="Actual">September 10, 2019</completion_date>
  <primary_completion_date type="Actual">August 23, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open labeled, single-center randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>gastrointestinal symptom</measure>
    <time_frame>baseline endoscopy (T0)</time_frame>
    <description>Upper Gastrointestinal Symptom Rating Scale (8 domain) : score : 0,1,2,3 in each domain (0: none, 3: severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gastrointestinal symptom</measure>
    <time_frame>within 24 hours after endoscopy (T1)</time_frame>
    <description>Upper Gastrointestinal Symptom Rating Scale (8 domain) : score : 0,1,2,3 in each domain (0: none, 3: severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gastrointestinal symptom</measure>
    <time_frame>3 days after endoscopy (T3)</time_frame>
    <description>Upper Gastrointestinal Symptom Rating Scale (8 domain) : score : 0,1,2,3 in each domain (0: none, 3: severe)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Gastrointestinal Symptom</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no medication after gastric biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration of sodium alginate (LaminaG) after gastric biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium alginate</intervention_name>
    <description>3 days oral administration of sodium alginate after gastric biopsy</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age from 18 to 80 years Persons who assigned on the written consent for the clinical trial.
        Persons who underwent upper endoscopy and gastric biopsy

        Exclusion Criteria:

        Gastrectomy Severe cardiovascular, pulmonary, or endocrine disease Renal or hepatic
        dysfunction Hematologic disease Gastric cancer Active peptic ulcer User of proton pump
        inhibitor, H2 blocker, mucoprotectant Immediate significant bleeding after biopsy Pregnant
        women Allergy history for sodium alginate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyungpook National University Hospital</investigator_affiliation>
    <investigator_full_name>Su Youn Nam</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

